Company profilePharmaceutical#521 of 1,318 in Pakistan✓ No DRAP alerts

PAKHEIM

Pharmaceutical company · 25 brands · 27 molecules

Ranked #62 of 311 companies in Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord)

25 registered products 13 pharmaceutical brands 27 distinct molecules 0 DRAP alerts

Company overview

25
registered products
13
pharmaceutical brands
27
distinct molecules
12
therapeutic classes
0
DRAP alerts

PAKHEIM is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 25 product registrations across 27 distinct molecules. Its portfolio is concentrated in Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord) and Antiinflammatory And Antirheumatic Products. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by PAKHEIM

1 product matched in our catalogue — each with its observed price and DRAP approved ceiling.

Allergy 1

Top molecules by brand count

Gabapentin1 brand
Salbutamol1 brand
Albuterol1 brand
Piroxicam-Beta-Cyclodextrin1 brand

Therapeutic classes

Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord) · 5Antiinflammatory And Antirheumatic Products · 5Drugs For Obstructive Airway Diseases, Systemic · 3Antiepileptics · 2Macrolides, Lincosamides And Streptogramins · 2Antiemetics & Antinauseants · 1Antifungal For Dermatological · 1Antianemic, Iron Preparations · 1Antibiotics For Topical Use · 1Other Beta-Lactam, Cephalosporins & Penems · 1Blood Glucose Lowering Drugs, Excluding Insulin · 1Topical Products For Joint And Muscular Pain · 1

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

SHROOQ PHARMACEUTICALS holds 22 molecules not in this portfolio
AcitretinAcyclovirAcyclovir Inf/OralCefiximeCiprofloxacinDiclofenac
BIO LABS (PVT) LTD. holds 139 molecules not in this portfolio
000 I.UAmlodipineAprepitantAremetherArtemetherArtesunate
PLATINUM PHARMACEUTICALS (PVT.) LTD. holds 123 molecules not in this portfolio
AlfacalcidolAmlodipineAmlodipine Base 10MgAmlodipine Base………….5MgAripiprazoleArtemether

Get the full profile for PAKHEIM

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.